Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Key points

• The novel IFNα-2b AOP2014 administered once every two weeks (or once a month) has low toxicity and induces high and sustained response rates in PV patients.
• AOP2014 induces significant partial and complete molecular response rates, as reflected by reduction of JAK2 allelic burden
• Click here for the complete article
• Details on the clinical trial at clinicaltrials.gov